



GREATER BOSTON INFUSION CENTER

17/19 Kendrick St, Wrentham, MA 02093

P 774-581-0032 | F 774-581-0033

PAGE 1

Ultomiris - Referral Checklist

Referral packet checklist

Complete this page and attach the supporting items below.

PATIENT & REFERRING PROVIDER

PATIENT NAME

DOB

DATE

REFERRING PROVIDER

NPI

DIRECT CONTACT / EXT.

OFFICE / PRACTICE

PHONE

FAX

EMAIL

URGENT CLINICAL CONTACT

REQUIRED REFERRAL PACKET

- ☐ Patient demographics and contact information
- ☐ Primary and secondary insurance information; front/back card copies
- ☐ Supporting clinical notes / office visits documenting Ultomiris treatment plan
- ☐ Current medication list and allergies
- ☐ Relevant laboratory results / imaging and baseline safety information
- ☐ Completed Ultomiris prescribing order (following page)

MEDICATION-SPECIFIC CLINICAL DOCUMENTATION

- Note should include any therapies tried/failed, and must include discussion about Ultomiris
- Medication list and allergies

GBIC INTERNAL USE

REFERRAL RECEIVED

BENEFITS VERIFIED

PA STATUS / THROUGH

SCHEDULED



GREATER BOSTON INFUSION CENTER

17/19 Kendrick St, Wrentham, MA 02093
P 774-581-0032 | F 774-581-0033

Prescribing Order - Ultomiris (ravulizumab)

☐ New Start

☐ Maintenance

DATE OF LAST DOSE / INFUSION

ORDER DETAILS

DATE OF ORDER

PATIENT NAME

DOB

M/F

DIAGNOSIS / ICD-10

☐ NKDA

PATIENT WEIGHT

ALLERGIES

PREMEDICATIONS

☐ Acetaminophen 1000mg PO

☐ Diphenhydramine 25mg IV

☐ Loratadine 10mg or Cetirizine 10mg PO

☐ Solu-medrol 125mg IV

☐ Diphenhydramine 25mg PO

☐ Other

LAB ORDERS

☐



GREATER BOSTON INFUSION CENTER

17/19 Kendrick St, Wrentham, MA 02093
P 774-581-0032 | F 774-581-0033

PAGE 3

Prescribing Order - Ultomiris (ravulizumab) (continued)

ULTOMIRIS MEDICATION ORDER

- ✓ Ultomiris IV dosing per table: Body Weight Loading Dose Maintenance Dose
40 - 60kg 2400mg 3000mg
60 - 100kg 2700mg 3300mg
>100kg 3000mg 3600mg
- ✓ Dilute Ultomiris in 0.9% Sodium Chloride for a final concentration of 5mg/ml and infuse via 0.22 micron filter at appropriate rate per weight per manufacturer medication guidelines
Frequency: ☐ Loading Dose ☐ Maintenance at week 2 and every 8 weeks
☐ Every 8 weeks

ADMINISTRATION & MONITORING

- ✓ Do not administer if patient has active signs or symptoms of infection.
- ✓ In case of infusion reaction, STOP infusion and follow GBIC infusion reaction protocol. Notify physician.
- ✓ Signature Date

PROVIDER AUTHORIZATION

ORDERING PROVIDER NAME

NPI

DATE

SIGNATURE

OFFICE PHONE / EXT.

Handwritten or compliant electronic signature